T1	Outcomes 164 187	safety and tolerability
T2	Outcomes 751 815	the frequency and severity of ocular and systemic adverse events
T3	Outcomes 838 880	were changes in BCVA and retinal thickness
T4	Outcomes 882 917	RESULTS No dose-limiting toxicities
T5	Outcomes 932 957	and ocular adverse events
T6	Outcomes 979 989	transient.
T7	Outcomes 990 1035	Conjunctival hyperemia, hemorrhage, and edema
T8	Outcomes 1082 1109	and conjunctival hemorrhage
T9	Outcomes 1171 1204	experienced ocular adverse events
T10	Outcomes 1242 1292	drug: Conjunctival edema and reduced visual acuity
T11	Outcomes 1369 1370	.
T12	Outcomes 1371 1403	No serious ocular adverse events
T13	Outcomes 1409 1418	reported.
T14	Outcomes 1419 1446	No nonocular adverse events
T15	Outcomes 1480 1485	drug.
T16	Outcomes 1486 1516	Systemic exposure to sirolimus
T17	Outcomes 1526 1551	with blood concentrations
T18	Outcomes 1630 1660	25), a median increase in BCVA
T19	Outcomes 1770 1810	45, median decrease in retinal thickness
T20	Outcomes 1854 1876	the median increase in
T21	Outcomes 1972 2022	letters); the median decrease in retinal thickness
